Drug intelligence / Profile preview

G0701

Development stage: Preclinical
Lead developer: GeneSail Biotech
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

G0701 is an investigational oncolytic virus therapy being developed by GeneSail Biotech for the treatment of solid tumors. It utilizes a vaccinia virus vector platform designed to selectively infect and replicate within malignant cells, leading to direct oncolysis. This process is intended to release tumor-associated antigens and danger signals into the tumor microenvironment, potentially stimulating a systemic anti-tumor immune response. Currently in the preclinical stage, G0701 is part of a series of oncolytic virus products developed by GeneSail Biotech targeting various solid tumor indications.

Beyond the preview

Go deeper on G0701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G0701.

Explore the full profile